For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for nearly 2 decades. In recent years, as its role has expanded into chronic weight management, healthcare professionals outside of these disciplines have begun to familiarize themselves with the class. In August 2023, it became evident cardiology would be the next specialty to find a role for at least one member of the class, with data from the SELECT and STEP-HFpEF trials purporting significant cardiovascular benefit from use of semaglutide 2.4 mg (Wegovy) in patient populations with obesity. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more